Microviable Therapeutics

Executive Summary

Microviable Therapeutics is a Spanish biotech company founded in 2019, based in Barcelona, with operations in Gijón and Oviedo. The company specializes in precision microbiome medicines for oncology and antibiotic-resistant infections, leveraging its proprietary PharmaBiota® drug discovery platform. Currently in Phase 1, Microviable is well-positioned to address significant unmet medical needs through novel biological therapeutics. The company's platform enables the identification and development of live biotherapeutic products (LBPs) that modulate the human microbiota to treat disease. With a strong scientific foundation and a focus on two high-need areas, Microviable has the potential to become a key player in the emerging microbiome therapeutics market. However, as a private, early-stage company, it faces typical risks including clinical trial outcomes, regulatory hurdles, and financing requirements.

Upcoming Catalysts (preview)

• Q4 2026Initiation of Phase 1b/2 trial for lead oncology candidate50% success
• Q2 2026Publication of preclinical data for antibiotic-resistant infection program70% success
• 2027Partnership or licensing deal with larger pharma for PharmaBiota platform40% success